Immunogenic Properties Studyoffusion Recombinant Proteins Based on VP6 and VP8 of Human Rotavirus A
https://doi.org/10.31631/2073-3046-2015-14-2-96-101
Abstract
Rotavirus infection is the leading cause of severe acute diarrhea among young children worldwide. Contagion with these viruses often leads to severe dehydration of organism. Rotaviral gastroenteritis cases may repeat intra vitam. Because of the absence of drugs with direct action on rotavirus, a timely vaccination is considered the most effective way of this disease's control. Nowadays vaccines based on attenuated alive rotaviral strains are used for this purpose, which can result in different complications. In this work the immunogenicity of recombinant fusion proteins VP6VP8 and FliCVP6VP8 - the crucial active agents of the candidate vaccine against rotaviruses - was studied. As part of the study highly purified proteins preparationsin native state were obtained, their high antigenic activity in experiments with laboratory Balb/c mice was demonstrated.
About the Authors
I. V. Dukhovlinov
Federal State Unitary Enterprise «Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency of Russian Federation
Russian Federation
Russian Federation
E. G. Bogomolova
Federal State Unitary Enterprise «Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency of Russian Federation
Russian Federation
Russian Federation
E. A. Fedorova
Federal State Unitary Enterprise «Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency of Russian Federation
Russian Federation
Russian Federation
A. S. Simbirtsev
Federal State Unitary Enterprise «Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency of Russian Federation
Russian Federation
Russian Federation
References
1. Shaw A.R. The rotavirus saga revisited. Ann. Rev. Med. 2013; 64: 165 – 174.
2. Schnagl R.D., Holmes I.H. Characteristics of the genome of human infantile enteritis virus (Rotavirus). J. Virol. 1976; 19 (1): 267 – 270.
3. Rodriguez W.J., Kim H.W., Arrobio J.O., Brandt C.D., Chanock R.M., Kapikian A.Z. et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J. Pediatr. 1977; 91 (2): 188 – 193.
4. Dennehy P.H. Treatment and prevention of rotavirus infection in children. Curr. Infect. Dis. Rep. 2013; 15 (3): 242 – 250.
5. Parashar U.D., Nelson E.A.S., Kang G. Diagnosis, management, and prevention of rotavirus gastroenteritis in children. BMJ. 2013; 347: 29 – 34.
6. Dukhovlinov I.V., Bogomolova E.G., Fedorova E.A., Simbirtsev A. S. Development of fusion recombinant proteins based on VP6 and VP8 of human rotavirus А. Russian Journal of Infection and Immunity. 2014; 4 (3): 229 – 234 (in Russian).
7. Invitrogen. Ni-NTA purification system. User manual. Cat. Nos K950-01 K951-01 K952-01 K953-01 K954-01 R901-01 R901-10 R 901-15. 2006: 32.
8. Li M., Su Z.-G., Janson J.-C. In vitro protein refolding by chromatographic procedures. Protein Expr. Purif. 2004; 33 (1): 1 – 10.
9. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227 (5259): 680 – 685.
10. The Ministry of Health of the USSR. Rules of work with experimental animals: 755. 1977 (in Russian).
11. Dennehy P.H. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 2008; 21 (1): 198 – 208.
12. Bruijning-Verhagen P., Mangen M.J., Felderhof M., Hartwig N.G., van Houten M., Winkel L. et al. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med. 2013; 11: 112.
13. Ben-Yedidia T., Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 1998; 64 (1): 9 – 15.
14. Balaram P., Kien P.K., Ismail A. Toll-like receptors and cytokines in immune responses to persistent mycobacterial and Salmonella infections. Int. J. Med. Microbiol. IJMM. 2009; 299 (3): 177 – 185.
15. Weimer E.T. Ervin S.E., Wozniak D.J., Mizel S.B. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine. 2009; 27 (48): 6762 – 6769.
16. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 2006;74 (2): 1113 – 1120.
17. Mizel S.B., Bates J.T. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. Baltim. Md 1950. 2010; 185 (10): 5677 – 5682.
Review
For citations:
Dukhovlinov I.V., Bogomolova E.G., Fedorova E.A., Simbirtsev A.S. Immunogenic Properties Studyoffusion Recombinant Proteins Based on VP6 and VP8 of Human Rotavirus A. Epidemiology and Vaccinal Prevention. 2015;14(2):96-101. (In Russ.) https://doi.org/10.31631/2073-3046-2015-14-2-96-101
Views:
702
Email this article 